{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:02:18Z","timestamp":1793253738131,"version":"4.5.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"7787","license":[{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2019,12,19]]},"DOI":"10.1038\/s41586-019-1841-8","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T14:03:18Z","timestamp":1576677798000},"page":"397-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Why and where an HIV cure is needed and how it might be achieved"],"prefix":"10.1038","volume":"576","author":[{"given":"Thumbi","family":"Ndung\u2019u","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"McCune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"key":"1841_CR1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter, G. et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692\u2013698 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1841_CR2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta, R. K. et al. HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation. Nature 568, 244\u2013248 (2019).Two HIV-infected adults\n1,2 with haematological malignancies were apparently cured of HIV after an effective stem-cell transplant from an allogeneic donor whose T cells lacked CCR5, a key co-receptor for virus entry.","journal-title":"Nature"},{"key":"1841_CR3","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","volume":"218","author":"G Namazi","year":"2018","unstructured":"Namazi, G. et al. The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies. J. Infect. Dis. 218, 1954\u20131963 (2018).","journal-title":"J. Infect. Dis."},{"key":"1841_CR4","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","volume":"9","author":"A S\u00e1ez-Ciri\u00f3n","year":"2013","unstructured":"S\u00e1ez-Ciri\u00f3n, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).A subset of HIV-infected adults who start ART early and remain on therapy for a sustained period are able to effectively control HIV replication after treatment interruption; although the mechanism(s) at play remain unclear, these \u2018post-treatment controllers\u2019 provide strong evidence that the host\u2013virus association can in some settings be slanted towards ART-free viral remission.","journal-title":"PLoS Pathog."},{"key":"1841_CR5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm.4108","volume":"22","author":"SG Deeks","year":"2016","unstructured":"Deeks, S. G. et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat. Med. 22, 839\u2013850 (2016).","journal-title":"Nat. Med."},{"key":"1841_CR6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter, W. D. F. et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N. Engl. J. Med. 381, 803\u2013815 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1841_CR7","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","volume":"381","author":"The NAMSAL ANRS 12313 Study Group","year":"2019","unstructured":"The NAMSAL ANRS 12313 Study Group. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N. Engl. J. Med. 381, 816\u2013826 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1841_CR8","doi-asserted-by":"crossref","first-page":"e011453","DOI":"10.1136\/bmjopen-2016-011453","volume":"6","author":"S Rueda","year":"2016","unstructured":"Rueda, S. et al. Examining the associations between HIV-related stigma and health outcomes in people living with HIV\/AIDS: a series of meta-analyses. BMJ Open 6, e011453 (2016).","journal-title":"BMJ Open"},{"key":"1841_CR9","volume":"16","author":"IT Katz","year":"2013","unstructured":"Katz, I. T. et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J. Int. AIDS Soc. 16, 18640 (2013).","journal-title":"J. Int. AIDS Soc."},{"key":"1841_CR10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/aid.2014.0200","volume":"31","author":"CE Chu","year":"2015","unstructured":"Chu, C. E. et al. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. AIDS Res. Hum. Retroviruses 31, 78\u201384 (2015).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"1841_CR11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.2018.21167","volume":"321","author":"RW Eisinger","year":"2019","unstructured":"Eisinger, R. W., Dieffenbach, C. W. & Fauci, A. S. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. J. Am. Med. Assoc. 321, 451\u2013452 (2019).","journal-title":"J. Am. Med. Assoc."},{"key":"1841_CR12","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","volume":"393","author":"AJ Rodger","year":"2019","unstructured":"Rodger, A. J. et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 393, 2428\u20132438 (2019).","journal-title":"Lancet"},{"key":"1841_CR13","unstructured":"UNAIDS. Global HIV & AIDS Statistics \u2014 2019 Fact Sheet https:\/\/www.unaids.org\/en\/resources\/fact-sheet (2019)"},{"key":"1841_CR14","doi-asserted-by":"crossref","DOI":"10.1186\/s41256-019-0107-1","volume":"4","author":"L Beacroft","year":"2019","unstructured":"Beacroft, L. & Hallett, T. B. The potential impact of a \u201ccurative intervention\u201d for HIV: a modelling study. Glob. Health Res. Policy 4, 18 (2019).","journal-title":"Glob. Health Res. Policy"},{"key":"1841_CR15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/QAD.0000000000002052","volume":"33","author":"DF Cuadros","year":"2019","unstructured":"Cuadros, D. F. et al. Towards UNAIDS Fast-Track goals: targeting priority geographic areas for HIV prevention and care in Zimbabwe. AIDS 33, 305\u2013314 (2019).","journal-title":"AIDS"},{"key":"1841_CR16","unstructured":"GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV 6, e831\u2013e859 (2019)."},{"key":"1841_CR17","doi-asserted-by":"crossref","first-page":"e0204840","DOI":"10.1371\/journal.pone.0204840","volume":"13","author":"S Moyo","year":"2018","unstructured":"Moyo, S. et al. Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013\u20132015. PLoS ONE 13, e0204840 (2018).","journal-title":"PLoS ONE"},{"key":"1841_CR18","unstructured":"UNAIDS. Fast-Track Update On Investments Needed In The AIDS Response https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_Reference_FastTrack_Update_on_investments_en.pdf (2016)."},{"key":"1841_CR19","first-page":"70","volume":"91","author":"A Gelpi","year":"2015","unstructured":"Gelpi, A. & Tucker, J. D. A cure at last? Penicillin\u2019s unintended consequences on syphilis control, 1944\u20131964. Sex. Transm. Infect. 91, 70 (2015).","journal-title":"Sex. Transm. Infect."},{"key":"1841_CR20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295\u20131300 (1997).","journal-title":"Science"},{"key":"1841_CR21","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","volume":"278","author":"JK Wong","year":"1997","unstructured":"Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291\u20131295 (1997).","journal-title":"Science"},{"key":"1841_CR22","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","volume":"94","author":"TW Chun","year":"1997","unstructured":"Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94, 13193\u201313197 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1841_CR23","doi-asserted-by":"crossref","first-page":"E3659","DOI":"10.1073\/pnas.1617961114","volume":"114","author":"A Wiegand","year":"2017","unstructured":"Wiegand, A. et al. Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART. Proc. Natl Acad. Sci. USA 114, E3659\u2013E3668 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1841_CR24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41591-018-0017-7","volume":"24","author":"LB Cohn","year":"2018","unstructured":"Cohn, L. B. et al. Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. Nat. Med. 24, 604\u2013609 (2018).Using single-cell analyses, the transcriptional profile of HIV-infected CD4\n+ T cells was characterized, revealing the expression of pathways that suppress HIV transcription.","journal-title":"Nat. Med."},{"key":"1841_CR25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.immuni.2018.04.004","volume":"48","author":"H-H Kuo","year":"2018","unstructured":"Kuo, H.-H. et al. Anti-apoptotic protein BIRC5 maintains survival of HIV-1-infected CD4+ T cells. Immunity 48, 1183\u20131194 (2018).","journal-title":"Immunity"},{"key":"1841_CR26","doi-asserted-by":"crossref","first-page":"eaap9927","DOI":"10.1126\/scitranslmed.aap9927","volume":"10","author":"SA Yukl","year":"2018","unstructured":"Yukl, S. A. et al. HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci. Transl. Med. 10, eaap9927 (2018).Multiple blocks to HIV transcription exist in infected CD4\n+ T cells; it may be necessary to overcome each using diverse approaches before sufficient amounts of HIV protein are made for the cell to be recognized and eliminated.","journal-title":"Sci. Transl. Med."},{"key":"1841_CR27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","volume":"155","author":"YC Ho","year":"2013","unstructured":"Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540\u2013551 (2013).Most (>90%) integrated HIV genomes are defective and unable to support HIV replication, complicating the measurement of the inducible replication-competent viral reservoir.","journal-title":"Cell"},{"key":"1841_CR28","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1084\/jem.20170193","volume":"214","author":"NN Hosmane","year":"2017","unstructured":"Hosmane, N. N. et al. Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics. J. Exp. Med. 214, 959\u2013972 (2017).","journal-title":"J. Exp. Med."},{"key":"1841_CR29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature21710","volume":"543","author":"B Descours","year":"2017","unstructured":"Descours, B. et al. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature 543, 564\u2013567 (2017).","journal-title":"Nature"},{"key":"1841_CR30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893\u2013900 (2009).","journal-title":"Nat. Med."},{"key":"1841_CR31","doi-asserted-by":"crossref","first-page":"e1005761","DOI":"10.1371\/journal.ppat.1005761","volume":"12","author":"R Fromentin","year":"2016","unstructured":"Fromentin, R. et al. CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog. 12, e1005761 (2016).","journal-title":"PLoS Pathog."},{"key":"1841_CR32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nm.4113","volume":"22","author":"R Banga","year":"2016","unstructured":"Banga, R. et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754\u2013761 (2016).During effective antiretroviral therapy, transcriptionally active HIV is enriched in PD-1-expressing T follicular helper cells that reside in lymph nodes.","journal-title":"Nat. Med."},{"key":"1841_CR33","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.immuni.2017.09.018","volume":"47","author":"CS McGary","year":"2017","unstructured":"McGary, C. S. et al. CTLA-4+PD-1\u2212 memory CD4+ T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-infected rhesus macaques. Immunity 47, 776\u2013788 (2017).","journal-title":"Immunity"},{"key":"1841_CR34","doi-asserted-by":"crossref","first-page":"e1005349","DOI":"10.1371\/journal.ppat.1005349","volume":"12","author":"GM Chew","year":"2016","unstructured":"Chew, G. M. et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLoS Pathog. 12, e1005349 (2016).","journal-title":"PLoS Pathog."},{"key":"1841_CR35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.celrep.2017.09.081","volume":"21","author":"B Hiener","year":"2017","unstructured":"Hiener, B. et al. Identification of genetically intact HIV-1 proviruses in specific CD4+ T cells from effectively treated participants. Cell Rep. 21, 813\u2013822 (2017).","journal-title":"Cell Rep."},{"key":"1841_CR36","doi-asserted-by":"crossref","first-page":"e1006856","DOI":"10.1371\/journal.ppat.1006856","volume":"14","author":"LE Hogan","year":"2018","unstructured":"Hogan, L. E. et al. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS Pathog. 14, e1006856 (2018).","journal-title":"PLoS Pathog."},{"key":"1841_CR37","doi-asserted-by":"crossref","first-page":"e1007619","DOI":"10.1371\/journal.ppat.1007619","volume":"15","author":"M Pardons","year":"2019","unstructured":"Pardons, M. et al. Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection. PLoS Pathog. 15, e1007619 (2019).","journal-title":"PLoS Pathog."},{"key":"1841_CR38","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/QAD.0000000000001029","volume":"30","author":"G Khoury","year":"2016","unstructured":"Khoury, G. et al. Persistence of integrated HIV DNA in CXCR3\u200a+\u200aCCR6\u200a+\u200amemory CD4+ T cells in HIV-infected individuals on antiretroviral therapy. AIDS 30, 1511\u20131520 (2016).","journal-title":"AIDS"},{"key":"1841_CR39","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1172\/JCI93289","volume":"127","author":"GQ Lee","year":"2017","unstructured":"Lee, G. Q. et al. Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J. Clin. Invest. 127, 2689\u20132696 (2017).","journal-title":"J. Clin. Invest."},{"key":"1841_CR40","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-016-0293-6","volume":"13","author":"VS Wacleche","year":"2016","unstructured":"Wacleche, V. S. et al. New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology 13, 59 (2016).","journal-title":"Retrovirology"},{"key":"1841_CR41","doi-asserted-by":"crossref","first-page":"E2575","DOI":"10.1073\/pnas.1720665115","volume":"115","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proc. Natl Acad. Sci. USA 115, E2575\u2013E2584 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1841_CR42","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.1256304","volume":"345","author":"TA Wagner","year":"2014","unstructured":"Wagner, T. A. et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570\u2013573 (2014).","journal-title":"Science"},{"key":"1841_CR43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.1254194","volume":"345","author":"F Maldarelli","year":"2014","unstructured":"Maldarelli, F. et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179\u2013183 (2014).As demonstrated in these two studies\n42,43, proliferation of memory T cells is the main mechanism by which the reservoir is maintained indefinitely; during long-term therapy, the population of infected cells becomes increasingly clonal with integration of defective HIV genomes in genes associated with cell growth (including oncogenes) and\/or within intergenic regions or silent genes.","journal-title":"Science"},{"key":"1841_CR44","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.cell.2015.01.020","volume":"160","author":"LB Cohn","year":"2015","unstructured":"Cohn, L. B. et al. HIV-1 integration landscape during latent and active infection. Cell 160, 420\u2013432 (2015).","journal-title":"Cell"},{"key":"1841_CR45","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI124291","volume":"129","author":"KB Einkauf","year":"2019","unstructured":"Einkauf, K. B. et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J. Clin. Invest. 129, 988\u2013998 (2019).","journal-title":"J. Clin. Invest."},{"key":"1841_CR46","doi-asserted-by":"crossref","first-page":"e34655","DOI":"10.7554\/eLife.34655","volume":"7","author":"E Battivelli","year":"2018","unstructured":"Battivelli, E. et al. Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells. eLife 7, e34655 (2018).","journal-title":"eLife"},{"key":"1841_CR47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08431-7","volume":"10","author":"MR Pinzone","year":"2019","unstructured":"Pinzone, M. R. et al. Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. Nat. Commun. 10, 728 (2019).","journal-title":"Nat. Commun."},{"key":"1841_CR48","volume":"10","author":"GQ Lee","year":"2019","unstructured":"Lee, G. Q. et al. HIV-1 DNA sequence diversity and evolution during acute subtype C infection. Nat. Commun. 10, 2737 (2019).","journal-title":"Nat. Commun."},{"key":"1841_CR49","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1172\/JCI97555","volume":"128","author":"SH Huang","year":"2018","unstructured":"Huang, S. H. et al. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J. Clin. Invest. 128, 876\u2013889 (2018).","journal-title":"J. Clin. Invest."},{"key":"1841_CR50","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","volume":"111","author":"CV Fletcher","year":"2014","unstructured":"Fletcher, C. V. et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl Acad. Sci. USA 111, 2307\u20132312 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1841_CR51","doi-asserted-by":"crossref","first-page":"e1004010","DOI":"10.1371\/journal.ppat.1004010","volume":"10","author":"MF Kearney","year":"2014","unstructured":"Kearney, M. F. et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 10, e1004010 (2014).","journal-title":"PLoS Pathog."},{"key":"1841_CR52","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","volume":"36","author":"L Shan","year":"2012","unstructured":"Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491\u2013501 (2012).","journal-title":"Immunity"},{"key":"1841_CR53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.4156","volume":"22","author":"KM Bruner","year":"2016","unstructured":"Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381\u2013385 (2015).","journal-title":"Nat. Med."},{"key":"1841_CR54","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1128\/JVI.01153-09","volume":"83","author":"SA Migueles","year":"2009","unstructured":"Migueles, S. A. et al. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 83, 11876\u201311889 (2009).","journal-title":"J. Virol."},{"key":"1841_CR55","doi-asserted-by":"crossref","first-page":"e1002840","DOI":"10.1371\/journal.ppat.1002840","volume":"8","author":"Y Peretz","year":"2012","unstructured":"Peretz, Y. et al. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog. 8, e1002840 (2012).","journal-title":"PLoS Pathog."},{"key":"1841_CR56","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1182\/blood-2010-12-322727","volume":"117","author":"AR Hersperger","year":"2011","unstructured":"Hersperger, A. R. et al. Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood 117, 3799\u20133808 (2011).","journal-title":"Blood"},{"key":"1841_CR57","doi-asserted-by":"crossref","DOI":"10.1038\/srep40354","volume":"7","author":"J Tauriainen","year":"2017","unstructured":"Tauriainen, J. et al. Perturbed CD8+ T cell TIGIT\/CD226\/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci. Rep. 7, 40354 (2017).","journal-title":"Sci. Rep."},{"key":"1841_CR58","doi-asserted-by":"crossref","first-page":"eaag1809","DOI":"10.1126\/scitranslmed.aag1809","volume":"9","author":"H Takata","year":"2017","unstructured":"Takata, H. et al. Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection. Sci. Transl. Med. 9, eaag1809 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1841_CR59","doi-asserted-by":"crossref","first-page":"eaau0528","DOI":"10.1126\/scitranslmed.aau0528","volume":"11","author":"ZM Ndhlovu","year":"2019","unstructured":"Ndhlovu, Z. M. et al. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. Sci. Transl. Med. 11, eaau0528 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1841_CR60","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.immuni.2015.08.012","volume":"43","author":"ZM Ndhlovu","year":"2015","unstructured":"Ndhlovu, Z. M. et al. Magnitude and kinetics of CD8+ T cell activation during hyperacute HIV infection impact viral set point. Immunity 43, 591\u2013604 (2015).Studies\n58\u201360 have shown that acute HIV infection is associated with a large CD8\n+ T cell response, which is initially effective but rapidly becomes less functional.","journal-title":"Immunity"},{"key":"1841_CR61","doi-asserted-by":"crossref","first-page":"e1003347","DOI":"10.1371\/journal.ppat.1003347","volume":"9","author":"SA Yukl","year":"2013","unstructured":"Yukl, S. A. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347 (2013).","journal-title":"PLoS Pathog."},{"key":"1841_CR62","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","volume":"24","author":"DJ Colby","year":"2018","unstructured":"Colby, D. J. et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat. Med. 24, 923\u2013926 (2018).","journal-title":"Nat. Med."},{"key":"1841_CR63","doi-asserted-by":"crossref","first-page":"e1002417","DOI":"10.1371\/journal.pmed.1002417","volume":"14","author":"TJ Henrich","year":"2017","unstructured":"Henrich, T. J. et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. PLoS Med. 14, e1002417 (2017).Studies\n62,63 have demonstrated that even with highly effective interventions that result in multi-log reductions in the reservoir, a small undetectable reservoir of replication-competent HIV can persist and rebound many months after ART is interrupted.","journal-title":"PLoS Med."},{"key":"1841_CR64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/M14-1027","volume":"161","author":"TJ Henrich","year":"2014","unstructured":"Henrich, T. J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319\u2013327 (2014).","journal-title":"Ann. Intern. Med."},{"key":"1841_CR65","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa1302976","volume":"369","author":"D Persaud","year":"2013","unstructured":"Persaud, D. et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828\u20131835 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1841_CR66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13287-2","volume":"7","author":"S Fidler","year":"2017","unstructured":"Fidler, S. et al. A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study. Sci. Rep. 7, 13658 (2017).","journal-title":"Sci. Rep."},{"key":"1841_CR67","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","volume":"566","author":"KM Bruner","year":"2019","unstructured":"Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120\u2013125 (2019).","journal-title":"Nature"},{"key":"1841_CR68","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.4411","volume":"23","author":"JD Estes","year":"2017","unstructured":"Estes, J. D. et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat. Med. 23, 1271\u20131276 (2017).","journal-title":"Nat. Med."},{"key":"1841_CR69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nmeth.3320","volume":"12","author":"PJ Santangelo","year":"2015","unstructured":"Santangelo, P. J. et al. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. Nat. Methods 12, 427\u2013432 (2015).","journal-title":"Nat. Methods"},{"key":"1841_CR70","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/infdis\/jix225","volume":"216","author":"SM Keating","year":"2017","unstructured":"Keating, S. M. et al. HIV antibody level as a marker of HIV persistence and low-level viral replication. J. Infect. Dis. 216, 72\u201381 (2017).","journal-title":"J. Infect. Dis."},{"key":"1841_CR71","doi-asserted-by":"crossref","first-page":"E1126","DOI":"10.1073\/pnas.1414926112","volume":"112","author":"MK Rothenberger","year":"2015","unstructured":"Rothenberger, M. K. et al. Large number of rebounding\/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc. Natl Acad. Sci. USA 112, E1126\u2013E1134 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1841_CR72","doi-asserted-by":"crossref","first-page":"eaan8848","DOI":"10.1126\/scitranslmed.aan8848","volume":"9","author":"MC Sneller","year":"2017","unstructured":"Sneller, M. C. et al. A randomized controlled safety\/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci. Transl. Med. 9, eaan8848 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1841_CR73","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/infdis\/jiz012","volume":"220","author":"J-D Leli\u00e8vre","year":"2019","unstructured":"Leli\u00e8vre, J.-D. & Hocqueloux, L. Unintended HIV-1 transmission to a sex partner in a study of a therapeutic vaccine candidate. J. Infect. Dis. 220, S5\u2013S6 (2019).","journal-title":"J. Infect. Dis."},{"key":"1841_CR74","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","volume":"6","author":"B Julg","year":"2019","unstructured":"Julg, B. et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials\u2014report of a consensus meeting. Lancet HIV 6, e259\u2013e268 (2019).","journal-title":"Lancet HIV"},{"key":"1841_CR75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/infdis\/jiw120","volume":"214","author":"AN Phillips","year":"2016","unstructured":"Phillips, A. N. et al. Identifying key drivers of the impact of an HIV cure intervention in sub-Saharan Africa. J. Infect. Dis. 214, 73\u201379 (2016).","journal-title":"J. Infect. Dis."},{"key":"1841_CR76","doi-asserted-by":"crossref","first-page":"ofx081","DOI":"10.1093\/ofid\/ofx081","volume":"4","author":"AD Paltiel","year":"2017","unstructured":"Paltiel, A. D. et al. Setting performance standards for a cost-effective human immunodeficiency virus cure strategy in South Africa. Open Forum Infect. Dis. 4, ofx081 (2017).","journal-title":"Open Forum Infect. Dis."},{"key":"1841_CR77","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3018(17)30146-7","volume":"5","author":"KL Dong","year":"2018","unstructured":"Dong, K. L. et al. Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study. Lancet HIV 5, e35\u2013e44 (2018).","journal-title":"Lancet HIV"},{"key":"1841_CR78","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/s41591-018-0130-7","volume":"24","author":"AA Okoye","year":"2018","unstructured":"Okoye, A. A. et al. Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat. Med. 24, 1430\u20131440 (2018).","journal-title":"Nat. Med."},{"key":"1841_CR79","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08311-0","volume":"10","author":"A Violari","year":"2019","unstructured":"Violari, A. et al. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat. Commun. 10, 412 (2019).","journal-title":"Nat. Commun."},{"key":"1841_CR80","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S2352-3018(15)00232-5","volume":"3","author":"P Frange","year":"2016","unstructured":"Frange, P. et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 3, e49\u2013e54 (2016).","journal-title":"Lancet HIV"},{"key":"1841_CR81","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.1663","volume":"28","author":"N Holt","year":"2010","unstructured":"Holt, N. et al. Human hematopoietic stem\/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28, 839\u2013847 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1841_CR82","doi-asserted-by":"crossref","first-page":"e1006956","DOI":"10.1371\/journal.ppat.1006956","volume":"14","author":"CW Peterson","year":"2018","unstructured":"Peterson, C. W. et al. Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: implications for HIV gene therapy. PLoS Pathog. 14, e1006956 (2018).","journal-title":"PLoS Pathog."},{"key":"1841_CR83","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcyt.2017.05.013","volume":"19","author":"KG Haworth","year":"2017","unstructured":"Haworth, K. G., Peterson, C. W. & Kiem, H. P. CCR5-edited gene therapies for HIV cure: closing the door to viral entry. Cytotherapy 19, 1325\u20131338 (2017).","journal-title":"Cytotherapy"},{"key":"1841_CR84","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd.2016.280","volume":"16","author":"H Yin","year":"2017","unstructured":"Yin, H., Kauffman, K. J. & Anderson, D. G. Delivery technologies for genome editing. Nat. Rev. Drug Discov. 16, 387\u2013399 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1841_CR85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41577-018-0085-4","volume":"19","author":"MP Davenport","year":"2019","unstructured":"Davenport, M. P. et al. Functional cure of HIV: the scale of the challenge. Nat. Rev. Immunol. 19, 45\u201354 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1841_CR86","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1056\/NEJMc1405805","volume":"371","author":"L Kordelas","year":"2014","unstructured":"Kordelas, L. et al. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N. Engl. J. Med. 371, 880\u2013882 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1841_CR87","volume":"10","author":"PK Dash","year":"2019","unstructured":"Dash, P. K. et al. Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. Nat. Commun. 10, 2753 (2019).","journal-title":"Nat. Commun."},{"key":"1841_CR88","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.celrep.2016.11.057","volume":"17","author":"G Wang","year":"2016","unstructured":"Wang, G., Zhao, N., Berkhout, B. & Das, A. T. A combinatorial CRISPR\u2013Cas9 attack on HIV-1 DNA extinguishes all infectious provirus in infected T cell cultures. Cell Rep. 17, 2819\u20132826 (2016).","journal-title":"Cell Rep."},{"key":"1841_CR89","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","volume":"50","author":"JM Martinez-Navio","year":"2019","unstructured":"Martinez-Navio, J. M. et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 50, 567\u2013575 (2019).","journal-title":"Immunity"},{"key":"1841_CR90","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","volume":"6","author":"FH Priddy","year":"2019","unstructured":"Priddy, F. H. et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV 6, e230\u2013e239 (2019).","journal-title":"Lancet HIV"},{"key":"1841_CR91","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","volume":"5","author":"SG Deeks","year":"2002","unstructured":"Deeks, S. G. et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5, 788\u2013797 (2002).","journal-title":"Mol. Ther."},{"key":"1841_CR92","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"1841_CR93","doi-asserted-by":"crossref","first-page":"e1006753","DOI":"10.1371\/journal.ppat.1006753","volume":"13","author":"A Zhen","year":"2017","unstructured":"Zhen, A. et al. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV\/AIDS. PLoS Pathog. 13, e1006753 (2017).","journal-title":"PLoS Pathog."},{"key":"1841_CR94","doi-asserted-by":"crossref","first-page":"e1006613","DOI":"10.1371\/journal.ppat.1006613","volume":"13","author":"RS Leibman","year":"2017","unstructured":"Leibman, R. S. et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog. 13, e1006613 (2017).","journal-title":"PLoS Pathog."},{"key":"1841_CR95","doi-asserted-by":"crossref","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","volume":"11","author":"K Anthony-Gonda","year":"2019","unstructured":"Anthony-Gonda, K. et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci. Transl. Med. 11, eaav5685 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1841_CR96","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482\u2013485 (2012).","journal-title":"Nature"},{"key":"1841_CR97","doi-asserted-by":"crossref","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","volume":"10","author":"JH Elliott","year":"2014","unstructured":"Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).","journal-title":"PLoS Pathog."},{"key":"1841_CR98","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","volume":"2","author":"JH Elliott","year":"2015","unstructured":"Elliott, J. H. et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2, e520\u2013e529 (2015).","journal-title":"Lancet HIV"},{"key":"1841_CR99","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","volume":"1","author":"TA Rasmussen","year":"2014","unstructured":"Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial. Lancet HIV 1, e13\u2013e21 (2014).","journal-title":"Lancet HIV"},{"key":"1841_CR100","doi-asserted-by":"crossref","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","volume":"11","author":"OS S\u00f8gaard","year":"2015","unstructured":"S\u00f8gaard, O. S. et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).","journal-title":"PLoS Pathog."},{"key":"1841_CR101","doi-asserted-by":"crossref","first-page":"eaao4521","DOI":"10.1126\/scitranslmed.aao4521","volume":"10","author":"S-Y Lim","year":"2018","unstructured":"Lim, S.-Y. et al. TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Sci. Transl. Med. 10, eaao4521 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1841_CR102","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/cid\/cix201","volume":"64","author":"L Vibholm","year":"2017","unstructured":"Vibholm, L. et al. Short-course Toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection. Clin. Infect. Dis. 64, 1686\u20131695 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"1841_CR103","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI80142","volume":"125","author":"GM Laird","year":"2015","unstructured":"Laird, G. M. et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J. Clin. Invest. 125, 1901\u20131912 (2015).","journal-title":"J. Clin. Invest."},{"key":"1841_CR104","doi-asserted-by":"crossref","first-page":"e122673","DOI":"10.1172\/jci.insight.122673","volume":"3","author":"AB Macedo","year":"2018","unstructured":"Macedo, A. B. et al. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight 3, e122673 (2018).","journal-title":"JCI Insight"},{"key":"1841_CR105","doi-asserted-by":"crossref","first-page":"e02084","DOI":"10.1128\/JVI.02084-16","volume":"91","author":"MA Rochat","year":"2017","unstructured":"Rochat, M. A., Schlaepfer, E. & Speck, R. F. Promising role of Toll-like receptor 8 agonist in concert with prostratin for activation of silent HIV. J. Virol. 91, e02084-16 (2017).","journal-title":"J. Virol."},{"key":"1841_CR106","doi-asserted-by":"crossref","first-page":"13475","DOI":"10.1073\/pnas.1406663111","volume":"111","author":"AL Hill","year":"2014","unstructured":"Hill, A. L., Rosenbloom, D. I., Fu, F., Nowak, M. A. & Siliciano, R. F. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc. Natl Acad. Sci. USA 111, 13475\u201313480 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1841_CR107","doi-asserted-by":"crossref","first-page":"e00465","DOI":"10.1128\/mBio.00465-15","volume":"6","author":"G Mousseau","year":"2015","unstructured":"Mousseau, G. et al. The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency. mBio 6, e00465-15 (2015).","journal-title":"mBio"},{"key":"1841_CR108","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","volume":"21","author":"CF Kessing","year":"2017","unstructured":"Kessing, C. F. et al. In vivo suppression of HIV rebound by didehydro-cortistatin A, a \u201cblock-and-lock\u201d strategy for HIV-1 treatment. Cell Rep. 21, 600\u2013611 (2017).","journal-title":"Cell Rep."},{"key":"1841_CR109","doi-asserted-by":"crossref","unstructured":"Barr, E. L. & Jefferys, R. A landscape analysis of HIV cure-related clinical trials and observational studies in 2018. J. Virus Eradication http:\/\/viruseradication.com\/journal-details\/A_landscape_analysis_of_HIV_cure-related_clinical_trials_and_observational_studies_in_2018\/ (2019).","DOI":"10.1016\/S2055-6640(20)30030-3"},{"key":"1841_CR110","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1073\/pnas.1419162112","volume":"112","author":"JM Conway","year":"2015","unstructured":"Conway, J. M. & Perelson, A. S. Post-treatment control of HIV infection. Proc. Natl Acad. Sci. USA 112, 5467\u20135472 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1841_CR111","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/infdis\/jit098","volume":"207","author":"JP Casazza","year":"2013","unstructured":"Casazza, J. P. et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J. Infect. Dis. 207, 1829\u20131840 (2013).","journal-title":"J. Infect. Dis."},{"key":"1841_CR112","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aac9475","volume":"351","author":"SG Hansen","year":"2016","unstructured":"Hansen, S. G. et al. Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E. Science 351, 714\u2013720 (2016).","journal-title":"Science"},{"key":"1841_CR113","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","volume":"502","author":"SG Hansen","year":"2013","unstructured":"Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100\u2013104 (2013).","journal-title":"Nature"},{"key":"1841_CR114","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nm.4063","volume":"22","author":"AJ Hessell","year":"2016","unstructured":"Hessell, A. J. et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat. Med. 22, 362\u2013368 (2016).","journal-title":"Nat. Med."},{"key":"1841_CR115","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nature20583","volume":"540","author":"EN Borducchi","year":"2016","unstructured":"Borducchi, E. N. et al. Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540, 284\u2013287 (2016).","journal-title":"Nature"},{"key":"1841_CR116","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","volume":"563","author":"EN Borducchi","year":"2018","unstructured":"Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360\u2013364 (2018).In these two related non-human primate studies\n115,116, a combination of immune therapies resulted in enhanced immune control and, in some cases, possible elimination of SIV\/SHIV; these strategies are now being tested in people.","journal-title":"Nature"},{"key":"1841_CR117","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"1841_CR118","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).These two related studies\n117,118 demonstrate that broadly neutralizing antibodies administered during a period of acute SHIV infection of non-human primates or immediately after interruption of ART in HIV-infected humans potentially induce long-term immune-mediated control (the \u2018vaccinal effect\u2019); in the case of SHIV-infected non-human primates, such suppression was shown to be mediated by CD8\n+ T cells.","journal-title":"Nature"},{"key":"1841_CR119","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","volume":"358","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358, 85\u201390 (2017).","journal-title":"Science"},{"key":"1841_CR120","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1172\/JCI82314","volume":"125","author":"JA Sung","year":"2015","unstructured":"Sung, J. A. et al. Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 125, 4077\u20134090 (2015).","journal-title":"J. Clin. Invest."},{"key":"1841_CR121","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14760584.2017.1322513","volume":"16","author":"L Leal","year":"2017","unstructured":"Leal, L. et al. New challenges in therapeutic vaccines against HIV infection. Expert Rev. Vaccines 16, 587\u2013600 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"1841_CR122","first-page":"480","volume":"364","author":"GD Gaiha","year":"2019","unstructured":"Gaiha, G. D. et al. Structural topology defines protective CD8+ T cell epitopes in the HIV proteome. Science 364, 480\u2013484 (2019).","journal-title":"proteome. Science"},{"key":"1841_CR123","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08798-7","volume":"10","author":"R Fromentin","year":"2019","unstructured":"Fromentin, R. et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nat. Commun. 10, 814 (2019).","journal-title":"Nat. Commun."},{"key":"1841_CR124","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/infdis\/jix191","volume":"215","author":"CL Gay","year":"2017","unstructured":"Gay, C. L. et al. Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J. Infect. Dis. 215, 1725\u20131733 (2017).","journal-title":"J. Infect. Dis."},{"key":"1841_CR125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/bloodadvances.2017012971","volume":"2","author":"GM Webb","year":"2018","unstructured":"Webb, G. M. et al. The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles. Blood Adv. 2, 76\u201384 (2018).","journal-title":"Blood Adv."},{"key":"1841_CR126","doi-asserted-by":"crossref","first-page":"eaag2285","DOI":"10.1126\/scitranslmed.aag2285","volume":"9","author":"C Petrovas","year":"2017","unstructured":"Petrovas, C. et al. Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Sci. Transl. Med. 9, eaag2285 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1841_CR127","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3018(15)00186-1","volume":"2","author":"J Ananworanich","year":"2015","unstructured":"Ananworanich, J. & Barr\u00e9-Sinoussi, F. Is it time to abandon single intervention cure trials? Lancet HIV 2, e410\u2013e411 (2015).","journal-title":"Lancet HIV"},{"key":"1841_CR128","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","volume":"3","author":"S Leth","year":"2016","unstructured":"Leth, S. et al. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial. Lancet HIV 3, e463\u2013e472 (2016).","journal-title":"Lancet HIV"},{"key":"1841_CR129","doi-asserted-by":"crossref","first-page":"e113031","DOI":"10.1371\/journal.pone.0113031","volume":"9","author":"PE Sax","year":"2014","unstructured":"Rossouw, T., Tucker, J. D., van Zyl G. U., Sikwesi, K. & Godfrey, C. Barriers to HIV remission research in low- and middle-income countries. J. Int. AIDS Soc. 20, 21521 (2017).","journal-title":"PLoS ONE"},{"key":"1841_CR130","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1172\/JCI97377","volume":"128","author":"C Kityo","year":"2018","unstructured":"Kityo, C. et al. Lymphoid tissue fibrosis is associated with impaired vaccine responses. J. Clin. Invest. 128, 2763\u20132773 (2018).","journal-title":"J. Clin. Invest."},{"key":"1841_CR131","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/infdis\/jiy617","volume":"219","author":"EP Scully","year":"2019","unstructured":"Scully, E. P. et al. Sex-based differences in human immunodeficiency virus type 1 reservoir activity and residual immune activation. J. Infect. Dis. 219, 1084\u20131094 (2019).","journal-title":"J. Infect. Dis."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41586-019-1841-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41586-019-1841-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41586-019-1841-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:00:57Z","timestamp":1684605657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1841-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":131,"journal-issue":{"issue":"7787","published-print":{"date-parts":[[2019,12,19]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1038\/s41586-019-1841-8","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,18]]},"assertion":[{"value":"23 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.G.D. receives grant support from Gilead, Merck and ViiV. He is a member of the scientific advisory boards for BryoLogyx and Enochian Biosciences and has consulted for AbbVie, Biotron and Eli Lilly. T.N. receives grant support from Gilead.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}